Avacincaptad pegol

Drug Profile

Avacincaptad pegol

Alternative Names: Anti-C5 aptamer; ARC-187; ARC-1905; Avacincaptad pegol sodium; Zimura

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Archemix Corporation
  • Developer OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration
  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 26 Jul 2017 Ophthotech plans a phase IIa trial for Choroidal neovascularisation (Idiopathic polypoidal choroidal vasculopathy; Combination therapy) in unknown countries by the end of 2017
  • 26 Jul 2017 Ophthotech plans a phase IIa trial for Uveitis (Intermediate/posterior) in unknown countries in early 2018
  • 26 Jul 2017 Ophthotech plans to cease enrolment in its phase IIa trial in Wet age-related macular degeneration Combination therapy) in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top